CA3218875A1 - Composes bifonctionnels de type protac ciblant pxr, leur procede de preparation et leur utilisation en therapeutique - Google Patents

Composes bifonctionnels de type protac ciblant pxr, leur procede de preparation et leur utilisation en therapeutique Download PDF

Info

Publication number
CA3218875A1
CA3218875A1 CA3218875A CA3218875A CA3218875A1 CA 3218875 A1 CA3218875 A1 CA 3218875A1 CA 3218875 A CA3218875 A CA 3218875A CA 3218875 A CA3218875 A CA 3218875A CA 3218875 A1 CA3218875 A1 CA 3218875A1
Authority
CA
Canada
Prior art keywords
pxr
compound
ligase
formula
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218875A
Other languages
English (en)
French (fr)
Inventor
Jean-Marc Pascussi
Julie Pannequin
Muriel AMBLARD-CAUSSIL
Guillaume Laconde
Sabine GERBAL-CHALOIN
Alain Chavanieu
William BOURGUET
Vanessa DELFOSSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Ecole Nationale Superieure de Chimie de Montpellier ENSCM
Universite de Montpellier
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Ecole Nationale Superieure de Chimie de Montpellier ENSCM
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Ecole Nationale Superieure de Chimie de Montpellier ENSCM, Universite de Montpellier filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CA3218875A1 publication Critical patent/CA3218875A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3218875A 2021-05-19 2022-05-18 Composes bifonctionnels de type protac ciblant pxr, leur procede de preparation et leur utilisation en therapeutique Pending CA3218875A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR2105217 2021-05-19
FR2105217A FR3122989B1 (fr) 2021-05-19 2021-05-19 Nouveaux composes bifonctionnels de type protac ciblant pxr, leur procede de preparation et leur utilisation en therapeutique
PCT/EP2022/063422 WO2022243365A1 (fr) 2021-05-19 2022-05-18 Composés bifonctionnels de type protac ciblant pxr, leur procédé de préparation et leur utilisation en thérapeutique

Publications (1)

Publication Number Publication Date
CA3218875A1 true CA3218875A1 (fr) 2022-11-24

Family

ID=76284058

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218875A Pending CA3218875A1 (fr) 2021-05-19 2022-05-18 Composes bifonctionnels de type protac ciblant pxr, leur procede de preparation et leur utilisation en therapeutique

Country Status (7)

Country Link
US (1) US20240252658A1 (https=)
EP (1) EP4340887A1 (https=)
JP (1) JP2024519536A (https=)
CN (1) CN117295523A (https=)
CA (1) CA3218875A1 (https=)
FR (1) FR3122989B1 (https=)
WO (1) WO2022243365A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118344284A (zh) * 2024-03-06 2024-07-16 杭州医学院 一种具有苯甲酰胺结构的化合物及其制备方法和应用
CN121735909A (zh) * 2024-09-27 2026-03-27 上海交通大学医学院附属瑞金医院 多价分子胶类化合物及其制备和应用
US20260092058A1 (en) 2024-09-30 2026-04-02 St. Jude Children's Research Hospital, Inc. Small Molecule Degraders and Fluorescent Probes of PXR

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223415A1 (en) * 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of tripartite motif-containing protein 24 (trim24) by conjugation of trim24 inhibitors with e3 ligase ligand and methods of use

Also Published As

Publication number Publication date
CN117295523A (zh) 2023-12-26
US20240252658A1 (en) 2024-08-01
FR3122989B1 (fr) 2024-03-29
EP4340887A1 (fr) 2024-03-27
JP2024519536A (ja) 2024-05-15
FR3122989A1 (fr) 2022-11-25
WO2022243365A1 (fr) 2022-11-24

Similar Documents

Publication Publication Date Title
CA3218875A1 (fr) Composes bifonctionnels de type protac ciblant pxr, leur procede de preparation et leur utilisation en therapeutique
EP1308447B1 (fr) Dérivé de purine pour utilisation dans le traitement d'un trouble prolifératif
JP2022093718A (ja) 協同的結合に関与する化合物及びその使用方法
UA128369C2 (uk) Сполуки, що інгібують rip1, а також способи їх одержання та застосування
US20250152590A1 (en) Nurr1:rxr activating compounds for simultaneous treatment of symptoms and pathology of parkinson's disease
US11998553B2 (en) Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
WO2019170150A1 (zh) 蛋白降解靶向bcr-abl化合物及其抗肿瘤应用
US10464890B2 (en) PGAM1 inhibitors and methods related thereto
EP1231916A2 (fr) Utilisation de derives d'indirubine pour la fabrication de medicaments
TW201121958A (en) Methods of treating hepatitis C virus with oxoacetamide compounds
US20110123510A1 (en) Methods of Affecting Biological Function Through Circadian Clock Feedback Cycle by NAMPT-Mediated NAD+ Biosynthesis
WO2020014524A1 (en) Methods for reversing hiv latency using baf complex modulating compounds
WO2021178663A1 (en) Compositions and methods for treatment of platinum-based chemotherapeutic resistant tumors
WO2015166041A1 (en) Flavones as cyp1a1 inhibitors for the treatment of cancer
KR20230117574A (ko) 암 치료를 위한 metap2 억제제 및 cdk4/6 억제제의 조합
KR20230067637A (ko) 근이영양증을 치료하기 위한 조성물 및 방법
EP2771344B1 (fr) Analogues de nucleosides pour le traitement d'une infection virale, et methode d'evaluation de la sensibilite audit traitement
JP2024102364A (ja) 貧血の処置におけるムスカリン性アセチルコリン受容体サブタイプ４アンタゴニスト
JP2022533151A (ja) キナゾリノン化合物、結晶形及びその製造方法
JP2023535224A (ja) 新規使用
CA2699590A1 (fr) Utilisation de derives de purine pour la fabrication d'un medicament
EP2605770A1 (en) Antifungal agents and uses thereof
JP2025144382A (ja) 化合物、アジュバント組成物および医薬組成物
CN116744928A (zh) 调节serca的喹啉及其治疗疾病的用途
FR3063903A1 (fr) Nouveaux composes, compositions et methodes pour le traitement de la resistance a l’insuline

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250117

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250514

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250514

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260409

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260409

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260422

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260422

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260422